A 3-year-old neutered male domestic shorthair cat was presented after 2 days of pollakiuria and hematuria; 2 hours of vocalization, stranguria, and dribbling urine; and a single episode of vomiting. Examination revealed 7% dehydration, tachycardia, and a firm, distended bladder; the remainder of the physical examination was within normal limits. CBC, serum chemistry profile, and urinalysis were unremarkable other than 4+ blood and presence of RBCs (TNTC) in the urine. Findings on abdominal ultrasonography likewise were unremarkable, with no evidence of calculi in the urinary tract.

The cat was treated with IV fluids, decompressive cystocentesis, and removal of an obstructive distal urethral mucus plug. An indwelling urinary catheter was maintained for 24 hours, then removed.
Which of the following drugs would be appropriate for this patient?
Based on the information provided, how would you grade the following drugs and why?

<table>
<thead>
<tr>
<th>Drug</th>
<th>RED</th>
<th>YELLOW</th>
<th>GREEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Prednisolone, dexamethasone</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Amoxicillin–clavulanate</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Prazosin</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Phenoxybenzamine</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Acepromazine</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Phenylpropanolamine</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Maropitant</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>RED</td>
<td>YELLOW</td>
<td>GREEN</td>
</tr>
</tbody>
</table>

TURN THE PAGE TO COMPARE YOUR RESULTS
Did you answer?

The following represents the best responses based on drug metabolism, pharmacokinetics, species, diagnostic differentials, clinical and laboratory data, and other pertinent findings.

**Buprenorphine**

Feline lower urinary tract signs are painful and most commonly associated with feline idiopathic cystitis (FIC). They are considered best managed by opioids in the acute phases of disease. Of the opioids, buprenorphine has the benefit of multiple routes of administration, including sublingual and subcutaneous, and is suitable for at-home use. Alternative analgesics have some disadvantages; for example, the sedative butorphanol has limited analgesic activity, and fentanyl is linked to respiratory depression, bradycardia, and urinary retention and requires more intensive patient monitoring than does buprenorphine.

**Meloxicam**

Multiple studies have failed to show a benefit of meloxicam treatment for the clinical course of FIC (eg, pain, duration) or for recurrence of urethral obstruction. Although renal injury is not apparent in this patient, NSAID use is contraindicated in patients with potential renal injury secondary to urinary outflow obstruction.

**Prednisolone, dexamethasone**

Anti-inflammatory doses of prednisolone or dexamethasone have been shown to have no positive effect on the clinical course of idiopathic feline lower urinary tract disease (FLUTD) or FIC.

**Amoxicillin–clavulanate**

Empiric use of antibiotics is not warranted in cats with urinary obstruction. Bacterial UTI is uncommon in cats presented with FLUTD, FIC, or urethral obstruction, especially those between 1 and 10 years of age, and antibiotic administration does not prevent catheter-related UTI. Antibiotics should not be administered to these cats unless bacterial infection is documented by urine culture. If lower urinary tract signs recur post-catheterization, obtaining a urine sample for culture at a return visit 3 to 4 days later is recommended to determine whether bacterial infection was introduced as a consequence of catheterization.

**Prazosin**

α₁-adrenergic blockers (ie, α₁ antagonists), which can cause urethral muscle relaxation, are often used in cats with urethral obstruction because of the potential contribution of urethral spasm (ie, functional obstruction) to initial or recurrent urethral blockage. Prazosin is the antispasmodic of choice because of its rapid onset of action and demonstrated superiority to phenoxybenzamine in impacting patient outcomes and less sedative effect as compared with acepromazine. Although urethral relaxants may appear to benefit individual patients, controlled studies have not shown a positive impact for their use in cats with FLUTD or FIC, possibly because only the preprostatic and prostatic urethra are affected by smooth muscle relaxants. Hypotension is a potential adverse effect of all α₁-adrenergic blockers used as urethral relaxants; these drugs should not be used in cats with hypovolemia or other conditions associated with pre-existing hypotension.
Phenoxybenzamine

Although phenoxybenzamine is commonly administered as a urethral relaxant in cats with urethral obstruction, this drug is less effective in reducing proximal urethral pressure than is prazosin or acepromazine and may require up to a week to show pharmacologic effect. In addition, cats with urethral obstruction treated with phenoxybenzamine were shown to have a significantly higher rate of recurrence of urethral obstruction as compared with cats treated with prazosin. As with prazosin, hypotension is a potential adverse effect, and thus phenoxybenzamine should not be used in cats with hypovolemia or other conditions associated with pre-existing hypotension.

Acepromazine

Acepromazine is effective in lowering proximal urethral pressures, but sedation is a common side effect. Because of its $\alpha_1$-adrenergic blocking effects, acepromazine can cause significant hypotension and thus should be avoided in hypovolemic patients.

Phenylpropanolamine

Phenylpropanolamine is a sympathomimetic drug used to treat urethral sphincter mechanism incompetence secondary to urethral sphincter hypotonia in dogs and cats. However, use of an agent that increases urethral sphincter tone is contraindicated in patients with urethral obstruction. The urine dribbling in this cat is likely related to small amounts of urine escaping past the urethral obstruction rather than from urethral sphincter hypotonus.

Maropitant

Antiemetic therapy is not indicated in this patient, as vomiting was most likely the result of urinary bladder distension and pain triggering peripheral afferent pathways to the emetic center. This triggering condition can be resolved by bladder decompression and pain management. In addition, a single episode of vomiting often does not warrant pharmacologic intervention. In a minority of cats with obstructive FLUTD or FIC, antiemetic therapy may be needed if they suffer severe metabolic consequences (eg, acute renal injury, acid-base and electrolyte derangements) of urinary obstruction and subsequent ongoing emesis. In addition to its antiemetic effect, maropitant may provide a visceral analgesic effect, however, its use as an analgesic in cats with lower urinary tract disease or urinary obstruction has not been evaluated.

FIC = feline idiopathic cystitis
FLUTD = feline lower urinary tract disease
Amitriptyline

Stress is thought to contribute to the development of FIC.9-11 Amitriptyline, a tricyclic antidepressant that has both anxiolytic and analgesic action, may be beneficial in managing patients with severe or recurrent disease. Side effects include sedation, salivation, urine retention, thrombocytopenia, and neutropenia. Although there is insufficient evidence to support use of amitriptyline as a short-term medication, long-term use of this drug may be considered if or when other evidence-based methods of control—which include moist diet, veterinary therapeutic urinary diet, and multimodal environmental modification or environmental enrichment21—have not delivered a desired response.

References